Artelo Biosciences Inc (NASDAQ: ARTL)’s stock price has gone rise by 6.19 in comparison to its previous close of 1.13, however, the company has experienced a 9.03% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-11 that SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo’s Board of Directors approved a 6-for-1 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”).
Is It Worth Investing in Artelo Biosciences Inc (NASDAQ: ARTL) Right Now?
Company’s 36-month beta value is 1.03.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARTL is 3.25M, and currently, short sellers hold a 5.93% ratio of that floaft. The average trading volume of ARTL on June 12, 2025 was 403.73K shares.
ARTL’s Market Performance
The stock of Artelo Biosciences Inc (ARTL) has seen a 9.03% increase in the past week, with a 20.00% rise in the past month, and a 26.32% gain in the past quarter. The volatility ratio for the week is 3.21%, and the volatility levels for the past 30 days are at 3.24% for ARTL. The simple moving average for the past 20 days is 16.83% for ARTL’s stock, with a 9.53% simple moving average for the past 200 days.
Analysts’ Opinion of ARTL
Many brokerage firms have already submitted their reports for ARTL stocks, with Ladenburg Thalmann repeating the rating for ARTL by listing it as a “Buy.” The predicted price for ARTL in the upcoming period, according to Ladenburg Thalmann is $7 based on the research report published on February 12, 2021 of the previous year 2021.
ARTL Trading at 20.61% from the 50-Day Moving Average
After a stumble in the market that brought ARTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.58% of loss for the given period.
#####
#####
Stock Fundamentals for ARTL
The total capital return value is set at -0.53. Equity return is now at value -190.70, with -140.10 for asset returns.
Based on Artelo Biosciences Inc (ARTL), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -127.11. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -2057.4.
Currently, EBITDA for the company is -10.29 million with net debt to EBITDA at 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.34.
Conclusion
In a nutshell, Artelo Biosciences Inc (ARTL) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
